GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foamix Pharmaceuticals Ltd (NAS:FOMX) » Definitions » Graham Number

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Graham Number : $N/A (As of Dec. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Foamix Pharmaceuticals Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-06), the stock price of Foamix Pharmaceuticals is $2.99. Foamix Pharmaceuticals's graham number for the quarter that ended in Dec. 2019 was $N/A. Therefore, Foamix Pharmaceuticals's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Foamix Pharmaceuticals's Graham Number or its related term are showing as below:

FOMX's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.14
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Foamix Pharmaceuticals Graham Number Historical Data

The historical data trend for Foamix Pharmaceuticals's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foamix Pharmaceuticals Graham Number Chart

Foamix Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Graham Number
Get a 7-Day Free Trial - - - - -

Foamix Pharmaceuticals Quarterly Data
Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Foamix Pharmaceuticals's Graham Number

For the Biotechnology subindustry, Foamix Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foamix Pharmaceuticals's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foamix Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Foamix Pharmaceuticals's Price-to-Graham-Number falls into.



Foamix Pharmaceuticals Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Foamix Pharmaceuticals's Graham Number for the fiscal year that ended in Dec. 2019 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*0.285*-1.66)
=N/A

Foamix Pharmaceuticals's Graham Number for the quarter that ended in Dec. 2019 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*0.285*-1.65)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foamix Pharmaceuticals  (NAS:FOMX) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Foamix Pharmaceuticals's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2019 )
=2.99/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Foamix Pharmaceuticals Graham Number Related Terms

Thank you for viewing the detailed overview of Foamix Pharmaceuticals's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Foamix Pharmaceuticals (Foamix Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Holzman Street, Weizmann Science Park, Rehovot, ISR, 7670402
Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.
Executives
Ilan Hadar officer: CFO & Country Manager C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Stanley Hirsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anna Kazanchyan director 933 MAMARONECK AVENUE, SUITE 103, MAMARONECK NY 10543
Anthony D Bruno director C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Stern director C/O THCG, INC, 650 MADISON AVENUE, 21ST FL, NEW YORK NY 10022
Rex Bright director 5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart officer: Chief Scientific Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski director, officer: CEO C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Mutya Harsch officer: CLO and General Counsel C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley officer: Chief Commercial Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Headlines

From GuruFocus

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

By Marketwired Marketwired 02-06-2020